Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$110.39 USD

110.39
58,745

-3.88 (-3.40%)

Updated Sep 6, 2024 12:35 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Amedisys Ties Up With Medalogix to Boost Home Health Unit

Amedisys (AMED) pursues deals to boost Home Health business.

    Here's Why You Should Invest in Veeva (VEEV) Stock Right Now

    Strong fundamentals and a solid Q2 aid Veeva (VEEV).

      Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost

      Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.

        Here's Why You Should Invest in Phibro (PAHC) Right Now

        Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.

          Here's Why You Should Buy Inogen (INGN) Stock Right Now

          Inogen (INGN) gains from strong Q2 results and bright global prospects.

            Here's Why You Should Invest in Genomic Health (GHDX) Now

            Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.

              Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit

              Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.

                New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales

                Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.

                  Wright Medical Buys Cartiva to Boost Lower Extremities Unit

                  Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.

                    STERIS (STE) Strategic Growth Strong, Competition a Woe

                    STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.

                      Bruker to Expand Molecular Diagnostics Arm With Hain Buyout

                      Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.

                        Omnicell Patient Engagement Unit to Aid Medication Adherence

                        Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.

                          Sweta Jaiswal headshot

                          Tap the Sleep Apnea Devices Market Boom With These 3 Stocks

                          Consider these three stocks in the sleep apnea devices market for grand returns.

                            Hill-Rom (HRC) Touches 52-Week High: What's Driving It?

                            Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.

                              Here's Why You Should Invest in Illumina (ILMN) Stock Now

                              Illumina (ILMN) gains on strategic partnerships and international prospects.

                                Ecolab's New Aquanomic Enhances Laundry Operations at Hotels

                                Ecolab's (ECL) new Aquanomic 2.0 Low-Temp Solid Laundry Program likely to boost Global Institutional segment.

                                  Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC

                                  Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.

                                    Masimo (MASI) Scales a 52-Week High: What's Driving It?

                                    Masimo's (MASI) solid guidance for 2018 and a broad product spectrum drive stock.

                                      Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                                      Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.

                                        Becton, Dickinson Hits at a 52-Week High: What's Driving It?

                                        Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.

                                          AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology

                                          AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.

                                            Wright Medical Strong Overseas, Back Order Issues Persist

                                            Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.

                                              Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children

                                              Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.

                                                Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance

                                                Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.

                                                  Masimo (MASI) Surpasses Q2 Earnings and Revenue Estimates

                                                  Masimo (MASI) delivered earnings and revenue surprises of 1.39% and 1.74%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?